
    
      This is a phase IV, multi-centre, open label prospective study of once daily Advagraf in 200
      patients undergoing kidney or liver transplantation in India. Adult patients undergoing
      kidney or liver transplantation and meeting all other eligibility criteria will be enrolled
      in the study. Enrolled patients will be administered once daily dose of Advagraf for 12
      weeks. During these 12 weeks a total of 9 regular visits will be undertaken.
    
  